Table 1.

Outcomes of Medical Therapies From American Urological Association’s Benign Prostatic Hyperplasia Guidelines Update

				Peak Flow Rate			QoL Question			BPH Impact
	AUA/IPSS			(Qmax)			Score			Index
	3–9	10–16	>16	3–9	10–16	>16	3–9	10–16	3–9	10–16
Therapy	Months	Months	Months	Months	Months	Months	Months	Months	Months	Months
Alpha blockers
Alfuzosin	−4.44			2.05			−1.10
Doxazosin	−5.10	−5.63		3.11	2.98	1.90*	−1.25	−1.47	−2.00	−2.47
Tamsulosin	−4.63	−7.53*		1.85	1.86*		−1.43
Terazosin	−6.22	−5.99		2.51	1.94	2.61*	−1.70*	−1.37	−1.45*	−2.09
Hormonal
Finasteride	−3.44	−3.40	−2.37	2.11	1.66	1.95	−0.75	−0.87	−1.50	−1.21
Combinations
Alfuzosin/finasteride	−6.10*			2.30*
Doxazosin/finasteride	−5.64	−6.53		3.96	3.38		−1.15	−1.57	−2.20	−2.57
Terazosin/finasteride	−5.90*	−6.21*		3.50*	2.63				−1.55*	−2.03
Placebo	−2.44*	−2.33*	−1.03*	0.86*	0.48*	0.48*	−0.65*	−0.67*	−1.00*	−0.97*

Numbers without asterisks are based on randomized, controlled trial (RCT) results with placebo controls.

^*Based on single-arm analyses; no RCT data available.

AUA. American Urological Association; BPH, benign prostatic hyperplasia; IPPS, International Prostate Symptom Score; QoL, quality of life. Reprinted with permission from The Journal of Urology, Volume 170, AUA Practice Guidelines Committee, AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations, p. 542, Copyright Elsevier 2003.⁶